Bassia scoparia

Bassia scoparia (Kochia scoparia): A Comprehensive Reference Article

1. Identity, Taxonomy, and Nomenclature

Bassia scoparia (L.) A.J. Scott is the currently accepted botanical name for the plant widely known in older scientific and medical literature as Kochia scoparia (L.) Schrad. The species was first published in 1753 by Carl Linnaeus, who named it Chenopodium scoparium. In 1809, it was placed in the genus Kochia by Heinrich Schrader. It was transferred to Bassia in 1978 by Andrew J. Scott, and Kochia was merged into Bassia in 2011 following phylogenetic studies.

Bassia All. is a genus from the Amaranthaceae family, which was created by merging selected species belonging to the former Bassia and Kochia genera with those classified to Chenolea, Londesia, Kirilowia, and Panderia. The reorganised Bassia genus currently comprises around 20 species, which are annual herbs or perennial subshrubs native to Eurasia and Africa.

Common synonyms appearing in the scientific and medical literature include:

• Kochia scoparia (L.) Schrad. (former primary name, still frequently used in TCM literature)
• Chenopodium scoparium L. (original Linnaean designation)
• Bassia sieversiana (Pall.) W.A. Weber
• Kochia trichophylla Stapf (ornamental variety)

Common names in English include burning bush, summer cypress, Mexican fireweed, and broom cypress. In Traditional Chinese Medicine (TCM), the dried fruit of the plant is known as Di Fu Zi (地肤子); the official pharmaceutical/herb name for the fruit is Kochiae Fructus (KF). In Japan, the processed fruits are used as a food garnish known as "Tonburi."

Bassia scoparia is native to a region ranging from Central Europe to Asia and is now widespread throughout the world. While having a variety of beneficial uses, it is also considered an invasive weed.

1.1 Plant Morphology and Natural Source

Kochiae Fructus (KF) is the fruit of an annual potherb Kochia scoparia (Linn.) Schrad., also called Bassia scoparia (L.) A.J. Scott, a large annual potherb in the family Chenopodiaceae widely distributed in Europe and Asia and naturalized in Africa, Australia, and North and South America.

Kochiae Fructus is the fruit of Kochia scoparia, which is a spheroidal pentagram with a diameter of 1 to 3 mm. The outer calyx is membranous, grayish-brown or reddish, with five wings arranged in the shape of a five-pointed star.

1.2 Common Forms and Preparations

The plant yields multiple medicinally relevant fractions and preparations:

• Kochiae Fructus (Di Fu Zi): The dried, mature fruits, collected in autumn. This is the primary pharmacological subject in TCM and pharmaceutical research. In autumn, when the fruits of Kochia scoparia are ripe, people gather them, dry them in the sun, take out their fruits, remove impurities, and make them into Chinese herbal medicine.
• Aqueous decoctions: Used internally in TCM practice; fruits are boiled in water.
• Ethanol extracts: Used in pharmacological research and increasingly in topical cosmetic/pharmaceutical preparations.
• Whole-plant extracts (WPBS): Research has begun to address the medicinal properties of non-fruit parts; diverse skin benefits of WPBS (whole-plant B. scoparia, excluding fruits), including its anti-photoaging, moisturizing, wound healing, anti-inflammatory, and anti-angiogenic effects, have been investigated.
• Topical formulations: Creams, washes, and poultices using the fruit extract.
• "Tonburi" food garnish: The plant is cultivated in some regions of Asia as a crop to collect Kochiae fructus, which is used for both curative and food purposes.

---

2. Traditional and Historical Use

2.1 Traditional Chinese Medicine (TCM)

Kochiae Fructus was first recorded in Shennong Ben Cao Jing ("The Divine Farmer's Classic of Materia Medica") as a "top grade" medicinal material. Up to now, KF has been used in traditional Chinese and Japanese medicine for more than 2000 years for the treatment of diseases of the skin, eyes, and urinary tract.

It is a relatively practical and common Chinese herbal medicine, which first appeared in Shennong Ben Cao Jing in the late Western Han Dynasty (around 100 BCE).

Within the TCM framework, Di Fu Zi is characterized as bitter and cold, entering the kidney and bladder meridians, and is used to clear heat and excrete dampness, and to dispel wind to alleviate itching.

For centuries, practitioners in China and Korea have utilized Kochia seeds, known as Di Fu Zi in TCM, for their therapeutic benefits. Historically, Kochia seeds were valued for their cooling and diuretic properties and were commonly administered to relieve discomfort from urinary tract infections, edema, and skin irritations such as eczema and pruritus.

In TCM combination formulas, Di Fu Zi is combined with herbs such as Mu Tong, Qu Mai, and Dong Kui Zi in Di Fu Zi Tang (from Ji Sheng Fang) for dysuria and painful urination due to damp-heat in the bladder; for damp-heat leucorrhea, it is usually combined with Huang Bai, Cang Zhu, and Che Qian Zi.

The seeds were often steeped in teas or ground into powders, providing a remedy for "damp-heat" conditions according to TCM philosophy.

2.2 Traditional Korean and Japanese Medicine

The dried fruit of Kochia scoparia (Chenopodiaceae) is used medicinally in Korea as a main ingredient in traditional herbal formulas indicated for external and internal applications for skin diseases and rheumatoid arthritis.

Kochia scoparia has also been mentioned as a treatment for liver disorders and used in traditional medicine for the alleviation of jaundice and edema.

In Japan, in addition to its medicinal use, the fruit was consumed as a food garnish called "Tonburi," the fruit of Japanese Kochia scoparia, and has been investigated for saponin constituents with bioactive properties.

2.3 Other Ethnobotanical Uses

Numerous ethnobotanical surveys carried out in different regions of Asia and Europe, records found in herbal books referring to traditional medicinal systems, and scientific literature reports all underline that Bassia plants have been intensively used by humans for therapeutic purposes and as nonmedical products.

Kochia has been used in Chinese and Korean folk medicine as a treatment for skin diseases, diabetes mellitus, and rheumatoid arthritis. Beyond East Asia, the plant has also been recorded in North African, Central Asian, and European folk traditions, primarily as a topical or diuretic remedy.

---

3. Key Chemical Constituents and Active Compounds

A total of 153 compounds have been identified in KF, mainly including triterpenoids, flavonoids, carbohydrates, amino acids, organic acids, and essential oils.

Specifically, 25 triterpenoids, 13 flavonoids, 22 carbohydrates, 21 amino acids, 9 organic acids, 49 essential oils, and 14 heterocyclics within KF have been reported.

3.1 Triterpenoids (Primary Active Fraction)

Most investigations indicate that triterpenoids are the main active ingredient within KF.

• Momordin Ic: Momordin Ic is the representative triterpene glycoside compound, which is used as a phytochemical marker for the quality control of Kochiae Fructus.
• Scoparianosides A, B, and C: Through bioassay-guided separation, momordin Ic and its 2'-O-beta-D-glucopyranoside, along with three new saponins named scoparianosides A, B, and C, were isolated as the active principles.
• 20-Hydroxyecdysone: A phytoecdysteroid also identified as a key bioactive compound, quantified alongside momordin Ic and oleanolic acid.
• Oleanolic acid: A pentacyclic triterpene identified in multiple fractions of the plant.

From ethyl-acetate-soluble portions of Kochia scoparia, twelve compounds have been isolated including tectorigenin, pratensein, iriflogenin, fumalic acid, N-trans-feruloylmethoxytyramine, N-transferuloyltyramine, stigmasterol, oleanolic acid, beta-stigmasterol, and daucosterol.

3.2 Flavonoids

Thirteen flavonoids have been identified in KF. Confirmed constituents from published chemical analyses include isoflavones (tectorigenin, pratensein, iriflogenin) and methylenedioxyflavone derivatives. The total flavonoids of KF have shown anti-inflammatory effects on dinitrochlorobenzene-induced allergic contact dermatitis in rats, and the most likely mechanism of this action involves regulating pERK1/2/TLR4-NF-κB pathway activation.

3.3 Other Compound Classes

Kochia scoparia contains triterpenoid glycosides, alkaloids, saponins, and many other compounds. The stem and leaves of the plant contain essential nutrients such as protein and fiber, carbohydrates, carotene, vitamin C, vitamin B1, vitamin B2, nicotinic acid, and trace elements.

Whole-plant extracts analyzed by LC-QTOF-MS have identified additional compounds: In negative ion mode, major compounds include D-xylulose, alpha-D-mannoheptulopyrranose, D-glyceric acid, ribonic acid, and gamma-aminobutyric acid (GABA). In positive ion mode, high abundance of stigmatellin Y and 4-aminobutyric acid (PABA) were detected, along with C16 sphinganine, adenine, butyl dodecanoate, pheophorbide a, and (E)-3-(2-hydroxyphenyl)-2-propenal.

3.4 Phytochemistry of the Broader Bassia Genus

Phytochemical studies carried out on Bassia species indicate that these plants synthesize metabolites belonging to different groups of compounds, including triterpene saponins, sterols, flavonoids, fatty acids, lignanamides, alkaloids, and organic acids. Some of the structures are rarely found in the plant kingdom.

---

4. Mechanisms of Action

4.1 Anti-inflammatory Mechanisms

Three triterpenoid saponins — 20-hydroxyecdysone, momordin Ic, and oleanolic acid from KF — have been investigated on LPS-stimulated murine macrophage RAW 264.7 cell line. 20-Hydroxyecdysone performed significant inhibitory action on prostaglandin E₂ (PGE₂) generation at a dose of 12.5 μM, while momordin Ic and oleanolic acid showed anti-inflammatory effects at a dose of 6.25 μM.

It has been reported that Kochia scoparia has a peripheral anti-nociceptive effect mediated by its anti-inflammatory actions, and this effect can be partially attributed to momordin Ic, a principal saponin constituent of Kochia scoparia.

4.2 Modulation of Cell Proliferation and Apoptosis (Wnt/β-Catenin Pathway)

Momordin Ic could inhibit HaCaT cell proliferation and enhance cell apoptosis; Momordin Ic also alters Wnt/β-catenin pathway activation. The Wnt/β-catenin signaling activator LiCl partially reversed the effects of Momordin Ic on HaCaT phenotypes and the Wnt/β-catenin pathway factors.

4.3 Anti-Photoaging and Dermatological Mechanisms

WPBS significantly reduced matrix metalloproteinase-1 (MMP-1) levels and increased collagen type I alpha 1 (COL1A1) levels (p < 0.01) in fibroblasts exposed to ultraviolet B (UVB) radiation. WPBS upregulated skin hydration markers such as aquaporin-3 (AQP3) and hyaluronan synthase-3 (HAS3) and effectively accelerated fibroblast wound closure compared to the positive control. Furthermore, WPBS substantially downregulated the expression of inflammatory markers (COX-2 and IL-1β) and angiogenic marker VEGF. Transcriptome analysis (RNA-seq) confirmed that WPBS suppressed inflammation-related and UV-induced gene expression pathways.

4.4 Glucose and Alcohol Absorption Inhibition

Through bioassay-guided separation, momordin Ic and its 2'-O-beta-D-glucopyranoside, with three new saponins named scoparianosides A, B, and C, were isolated as the active principles. Momordin Ic and its 2'-O-beta-D-glucopyranoside were found to potently inhibit glucose and ethanol absorption in rats.

4.5 Network Pharmacology Targets (Atopic Dermatitis)

Nineteen key phytochemicals from Kochiae Fructus and 268 potential targets have been identified using the Traditional Chinese Medicine Systems Pharmacology Database (TCMSP) and SwissTarget Prediction. PPI network analyses highlighted 78 anti-atopic dermatitis (AD) key targets, including SRC, MAPK3, MAPK1, JUN, PIK3CA, ESR1, PTGS2, PTPN11, IL-6, and ALOX5. Gene ontology enrichment analysis revealed that Kochiae Fructus affects biological processes such as positive regulation of the apoptotic response, inflammatory response, and hormone-mediated signaling pathways.

---

5. Scientific Evidence by Area of Use

Important caveat: The great majority of published scientific evidence for B. scoparia / K. scoparia is from in vitro (cell-culture) experiments and animal models. Very few prospective human clinical trials have been conducted. Evidence strength is characterized below for each area.

5.1 Dermatological Applications

Skin Inflammation and Pruritus

Recent pharmacology studies showed anti-inflammatory, antifungal, antiallergic, and antipruritogenic effects of KF, which supports the traditional clinical applications including the treatment of diseases in the skin, eye, and urinary tract in China, Korea, and Japan.

A series of studies have reported that the 70% ethanol extract, and its component momordin Ic, from the dried fruits of Kochia scoparia (Di Fu Zi) had antinociceptive and anti-inflammatory, antiallergic, and antipruritic effects.

Evidence strength: Primarily preclinical (in vitro and animal). The contact dermatitis and antipruritic effects have been demonstrated in rodent models but have not been confirmed in randomized controlled human clinical trials.

Anti-Photoaging

In a 2025 cell-based study, whole-plant B. scoparia extract (WPBS) significantly reduced MMP-1 levels and increased COL1A1 levels (p < 0.01) in fibroblasts exposed to UVB radiation, and upregulated skin hydration markers aquaporin-3 (AQP3) and hyaluronan synthase-3 (HAS3), while effectively accelerating fibroblast wound closure.

Evidence strength: In vitro only (keratinocyte and fibroblast cell lines); no human clinical data available as of the date of publication.

Psoriasis

Momordin Ic was demonstrated to inhibit HaCaT cell proliferation and enhance cell apoptosis, and was shown to alter Wnt/β-catenin pathway activation by affecting β-catenin nuclear distribution. This cell-based research provides a mechanistic rationale for the traditional use in psoriasis-type conditions, though human clinical trials have not been reported.

Evidence strength: In vitro (HaCaT human keratinocyte cell line). Preliminary; no clinical data.

Atopic Dermatitis (AD)

Fructus Kochiae has been used as an edible and topical drug in the treatment of skin, urinary, and eye diseases for more than 2000 years in China. Fructus Kochiae (or Kochia scoparia) has been reported to protect against skin inflammation related to evil heat, humidity, and wind, including atopic dermatitis.

A 2025 network pharmacology study identified molecular targets of Kochiae Fructus relevant to AD, but the study was computational in design (in silico) with no human clinical data.

Evidence strength: Animal models and in silico network pharmacology. No human RCT data.

5.2 Urinary Tract Disorders

Kochiae Fructus is recommended in TCM for urinary system disorders, such as frequent urination or urinary incontinence, and as a remedy in vaginal discharge. This use is well-documented in ethnobotanical records across more than two millennia but has not been subjected to controlled human clinical trials. No published RCTs investigating these endpoints were identified in the literature search.

Evidence strength: Traditional use only; no peer-reviewed human clinical evidence identified.

5.3 Antidiabetic / Hypoglycemic Effects

The methanolic extract of Kochia scoparia was found to inhibit the increase in serum glucose in glucose-loaded rats.

One of the major saponin constituents of Fructus Kochiae, Momordin Ic, has a number of biological activities, including controlling glucose-induced elevated blood sugar levels.

In vitro triterpenoid studies from KF demonstrated glucose uptake activity in 3T3-L1 adipocytes and α-glucosidase inhibition (investigated computationally via in silico molecular docking, published 2023). The hypoglycemic effects of KF have been tested.

Evidence strength: Preclinical (rodent in vivo, cell culture, in silico). No human clinical trials on antidiabetic endpoints have been published.

5.4 Hepatoprotective Effects

Momordin Ic and oleanolic acid from Kochiae Fructus were shown to reduce carbon tetrachloride-induced hepatotoxicity in rats.

Hepatoprotective effects of KF have been reported in preclinical models, consistent with the traditional use for jaundice. No human clinical data are available.

Evidence strength: Animal models only. No human clinical evidence.

5.5 Anti-obesity Effects

The effect of the ethanol extract of K. scoparia fruit was evaluated for prevention of obesity induced in mice.

Biological activity studies carried out on Bassia plants revealed various effects exerted by extracts and isolated compounds, including anti-obesity effects, among others.

Evidence strength: Animal models only. No human clinical evidence.

5.6 Antimicrobial and Antifungal Effects

Recent studies have shown antifungal effects of KF, clarifying the mechanisms of these actions.

A study investigating water-soluble seed exudates from Kochia scoparia found notable activity against plant-pathogenic fungi. Water-soluble exudates were found to inhibit Colletotrichum graminicola, the fungal causative agent of anthracnose and stalk rot in maize; the narrow range of fungi found as targets suggested the mechanism of inhibition may be specific rather than broadly antifungal.

Evidence strength: In vitro and animal models. These findings are preliminary and focused on pathogen-specific contexts; human clinical antimicrobial data are lacking.

5.7 Anti-rheumatoid Arthritis Effects

Anti-rheumatoid arthritis effects of the Kochia scoparia fruits and activity comparison of momordin Ic, its prosapogenin, and sapogenin have been studied. Research has been conducted primarily in animal models, and the constituent momordin Ic has shown anti-inflammatory activity consistent with reduced joint inflammation in preclinical contexts.

Evidence strength: Preclinical (animal and in vitro). No human clinical trials identified.

5.8 Anticancer Potential

Anticancer effects of KF have been reported in the scientific literature. Network-based pharmacology analysis with experimental validation has been published investigating the potential anti-oral squamous cell carcinoma mechanisms from Kochiae Fructus (2023). Momordin Ic has also shown pro-apoptotic effects.

Evidence strength: In vitro, network pharmacology, and in silico. No human clinical evidence. These findings are highly preliminary.

---

6. Body Systems and Health Areas Associated with B. scoparia

• Integumentary (skin) system: Pruritus, eczema, urticaria, contact dermatitis, atopic dermatitis, psoriasis, photoaging, wound healing, skin hydration.
• Urinary system: Dysuria, urinary frequency, urinary incontinence, gonorrhea (traditional use).
• Metabolic system: Hyperglycemia (antidiabetic effects), obesity prevention.
• Hepatic system: Jaundice, hepatotoxin-induced liver injury (hepatoprotection).
• Musculoskeletal system: Rheumatoid arthritis (traditional and preclinical).
• Immune / allergic system: Antiallergic and anti-inflammatory activity; pollen of the plant itself is a known allergen (see Safety section).
• Ophthalmic system: Eye diseases (traditional use, no human clinical evidence identified).
• Oncology: Emerging preclinical anticancer interest, particularly in skin and oral cancers.

---

7. Dosage Forms and Reported Doses

The following dosage information is drawn exclusively from published sources. There are no standardized Western-pharmacopoeial dosage recommendations for B. scoparia in Europe or North America. Dosages below are those reported in specific research contexts only.

• Pharmacological in vitro (anti-inflammatory): 20-Hydroxyecdysone showed significant inhibitory action on PGE₂ generation at a dose of 12.5 μM; momordin Ic and oleanolic acid showed anti-inflammatory effects at 6.25 μM (in LPS-stimulated RAW 264.7 macrophage cells).
• Whole-plant extract (in vitro, dermatology): WPBS extract was prepared via ultrasonic aqueous extraction of Bassia scoparia excluding fruits, followed by LC-QTOF-MS component analysis (specific mg/mL concentrations reported within the study).
• Acute oral toxicity (KM mice): Only one article reported that the LD₅₀ was 7.15 ± 0.03 g/kg for water extract of KF after oral administration in KM mice.
• Traditional TCM decoction: Historically prepared as a decoction with water; specific gram quantities per dose are described in TCM Materia Medica references but are not independently verifiable from the peer-reviewed sources accessed for this article.

No human clinical pharmacokinetic dose-response studies have been published for standardized extracts of B. scoparia. A pharmacokinetic study was carried out on momordin Ic showing linear pharmacokinetic characteristics, but detailed human pharmacokinetic parameters are not yet established in the public literature.

---

8. Safety Considerations

8.1 Toxicology — Fruit Extract (Kochiae Fructus)

There are few toxicology studies on KF, which may be necessary for its better application as a medicine or a food.

The research on toxicity is insufficient, and only one article reported that the LD₅₀ was 7.15 ± 0.03 g/kg for water extract of KF after oral administration in KM mice. This figure represents an acute oral lethal dose in a rodent model and cannot be directly extrapolated to human safety thresholds.

8.2 Pollen Allergenicity

Kochia scoparia pollen has been demonstrated as an important cause of pollinosis in tropical and sub-tropical regions of the world. A characterized allergen, designated Koc s 2, is a profilin protein identified from Kochia pollen with IgE-binding reactivity confirmed in sensitized patients. Nucleotide sequence homology of Kochia profilin was evaluated to predict its allergenic cross-reactivity with profilins of common allergenic plants. This means individuals sensitive to related pollen allergens may experience cross-reactive respiratory allergies when exposed to B. scoparia pollen — a distinct consideration from internal or topical medicinal use of the fruit or plant extract.

8.3 Livestock Hepatotoxicity

Kochia scoparia, commonly known as kochia weed, is a plant associated with liver disease in livestock, characterized by massive centrilobular hepatic necrosis and liver failure; however, its hepatotoxicity has not been experimentally proven.

Kochia weed is poisonous to cattle and sheep, causing a variety of clinical signs ranging from acute death, blindness, central nervous system depression, liver and kidney disease, and photosensitization.

Though kochia often accumulates nitrates and oxalates, no potential hepatic toxins have been definitively identified; saponins and some alkaloids seem to be the toxic compounds involved in liver damage and photosensitization.

These livestock toxicity data are important contextually: the whole plant, when consumed in large quantities as fodder, has been associated with serious toxicity in ruminants. These findings do not directly apply to the processed, dried fruit (Kochiae Fructus) used in human TCM practice, but they underscore the importance of distinguishing plant parts and preparation methods.

8.4 Nitrate and Oxalate Accumulation

The living plant, particularly the leafy vegetative material, is documented to accumulate nitrates and oxalates, which can contribute to toxic effects when consumed in large quantities. This accumulation property is relevant to food use (young leaves and stems) and to livestock grazing, but is of lesser concern for the processed, dried fruit preparation used medicinally.

8.5 Skin Sensitization via Topical Products

In vitro studies confirm that WPBS extract enhanced the viability of keratinocytes (HaCaT) without inducing cytotoxic effects, suggesting a reasonable safety profile at the concentrations tested in cell culture. However, topical sensitization potential in humans has not been systematically evaluated in published clinical trials.

8.6 Absence of Established Drug Interaction Data

No peer-reviewed human studies on drug-herb interactions involving B. scoparia preparations were identified in the literature accessed. Given the demonstrated in vitro effects on glucose metabolism, hepatic enzymes, and inflammatory mediators, the potential for pharmacodynamic interactions with antidiabetic drugs, hepatically metabolized pharmaceuticals, or immunosuppressants cannot be excluded but has not been formally investigated.

---

9. Summary of Evidence Strength

• Dermatological effects (anti-inflammatory, antipruritic, anti-photoaging): Multiple in vitro and animal studies support these effects; some mechanistic data are available; no human RCT evidence.
• Antidiabetic / hypoglycemic: Rodent in vivo and in vitro evidence; no human clinical trials.
• Hepatoprotective: Rodent model data only; paradoxically, the intact plant is a recognized hepatotoxin in livestock.
• Antimicrobial / antifungal: Preliminary in vitro evidence; no human data.
• Anti-obesity: Animal model data only; no human data.
• Anticancer: In vitro and in silico only; highly preliminary.
• Urinary tract disorders: Based entirely on traditional use; no controlled human evidence.

Biological activity studies carried out on Bassia plants revealed various effects exerted by extracts and isolated compounds, including anti-inflammatory, cytotoxic, antioxidant, antimicrobial, hypoglycemic, and anti-obesity effects. Modern research has explained some of the mechanisms of action. Nevertheless, the translation of these preclinical findings into validated clinical practice awaits rigorously designed human clinical trials, none of which had been published in the peer-reviewed literature as of the time of this writing.

References

• Zou W, Tang Z, Long Y, et al. Kochiae Fructus, the Fruit of Common Potherb Kochia scoparia (L.) Schrad: A Review on Phytochemistry, Pharmacology, Toxicology, Quality Control, and Pharmacokinetics. Evidence-Based Complementary and Alternative Medicine. 2021. PMC7868135.
• Jeong S, Kim HB, Lee DG, et al. Multifunctional Dermatological Effects of Whole-Plant Bassia scoparia Extract: Skin Repair and Protection. Current Issues in Molecular Biology. 2025;47(8):617. PMC12384579.
• Kochia scoparia Saponin Momordin Ic Modulates HaCaT Cell Proliferation and Apoptosis via the Wnt/β-Catenin Pathway. PMC8310444.
• Yoo SR, Jeong SJ, Lee NR, Shin HK, Seo CS. Quantification Analysis and In Vitro Anti-Inflammatory Effects of 20-Hydroxyecdysone, Momordin Ic, and Oleanolic Acid from the Fructus of Kochia scoparia. Pharmacognosy Magazine. 2017;13(51):339–344. PMC5551347.
• Current knowledge on genus Bassia All.: a comprehensive review on traditional use, phytochemistry, pharmacological activity, and nonmedical applications. Phytochemistry Reviews. Springer, 2023.
• Liu XX, Wang L, Wang Q, Qiu B. Study on chemical constituents of Kochia scoparia. Zhongguo Zhong Yao Za Zhi. 2007;32(10):921-3. PMID: 17655146.
• Topical application of Kochia scoparia inhibits the development of contact dermatitis in mice. Journal of Ethnopharmacology. 2014.
• Al-Snafi AE. A Review on Pharmacological Activities of Kochia scoparia. Indo American Journal of Pharmaceutical Sciences. 2018;05(04):2213–2221.
• Immunochemical and molecular characterization of allergenic profilin (Koc s 2) from Kochia scoparia pollen. Applied Biological Chemistry. 2015.
• Kochia scoparia — ScienceDirect Topics. Haschek and Rousseaux's Handbook of Toxicologic Pathology. 2023.
• Kochia Weed Hepatotoxicity in Livestock. USDA National Agricultural Library.
• Water-soluble exudates from seeds of Kochia scoparia exhibit antifungal activity against Colletotrichum graminicola. PMC6584005.
• Bassia scoparia — Wikipedia (taxonomic history and distribution).
• Network pharmacology and in silico analysis reveal Kochiae Fructus as a potential therapeutic against atopic dermatitis through immunomodulatory pathway interactions. PMC11967982.
• A Mixture of Extracts of Kochia scoparia and Rosa multiflora with PPARα/γ Dual Agonistic Effects Prevents Photoaging in Hairless Mice. PMC5133916.